New drug shows promise for brain tumors from breast and lung cancer

NCT ID NCT05305365

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a drug called QBS72S in 21 adults with breast or lung cancer that has spread to the brain. The drug is given once a month through an IV. The main goal is to see if it shrinks brain tumors. The trial is active but not recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

QBS72S (also called QBS10072S), a drug given by IV once a month

What this could lead to

If it works, this could point toward a new treatment option for people with cancer that has spread to the brain.

What could go wrong

This is a small, early-phase trial with only 21 participants, so results may not apply widely. The drug may not shrink tumors or improve survival, and side effects are still being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast neoplasm Langer mesomelic dysplasia lung cancer lung neoplasm Meningeal Neoplasms metastatic malignant neoplasm in the brain neoplastic meningitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Stanford Cancer Institute

    Palo Alto, California, 94305, United States